Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simone Ferrero

Showing results (351-360 of 481) with videos related to

Pageof 49
Sort By:
Expert Opinion on Investigational Drugs|February 3, 2015
Investigational therapies currently in Phase II clinical trials for the treatment of pelvic serous carcinomasAlice Bergamini, Umberto Leone Roberti Maggiore, Simone Ferrero, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 26, 2024
Endometriosis-associated ovarian cancer: a different clinical entityUmberto Leone Roberti Maggiore, G Bogani, Biagio Paolini, et al.
Journal of Gynecologic Oncology|May 11, 2019
Efficacy and fertility outcomes of levonorgestrel-releasing intra-uterine system treatment for patients with atypical complex hyperplasia or endometrial cancer: a retrospective studyUmberto Leone Roberti Maggiore, Fabio Martinelli, Giulia Dondi, et al.
Expert Opinion on Investigational Drugs|July 19, 2021
Linzagolix: a new GnRH-antagonist under investigation for the treatment of endometriosis and uterine myomasSusan Dababou, Simone Garzon, Antonio Simone Laganà, et al.
Critical Reviews in Oncology/Hematology|May 16, 2018
Role of bevacizumab in uterine leiomyosarcomaGiorgio Bogani, Antonino Ditto, Fabio Martinelli, et al.
Hemasphere|May 26, 2023
Unmet Clinical Needs in the Management of Idiopathic Multicentric Castleman Disease: A Consensus-based Position Paper From an ad hoc Expert PanelPier Luigi Zinzani, Marco Paulli, Luca Arcaini, et al.
Expert Opinion on Investigational Drugs|November 1, 2016
Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancerAlice Bergamini, Simone Ferrero, Umberto Leone Roberti Maggiore, et al.
Annals of Medicine|September 3, 2021
Efficacy and safety of prolonged-release hyaluronic acid derivative vaginal application in the postpartum period: a prospective randomised clinical trialClaudio Gustavino, Paolo Sala, Nadia Cusini, et al.
Drugs|October 14, 2023
Current Medical Therapy for Adenomyosis: From Bench to BedsideAndrea Etrusco, Fabio Barra, Vito Chiantera, et al.
Annals of Hematology|April 23, 2016
Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective studyPatrizia Mondello, Normann Steiner, Wolfgang Willenbacher, et al.
Pageof 49

Showing results (351-360 of 481) with videos related to

Sort By:
Pageof 49
Expert Opinion on Investigational Drugs|February 3, 2015
Investigational therapies currently in Phase II clinical trials for the treatment of pelvic serous carcinomasAlice Bergamini, Umberto Leone Roberti Maggiore, Simone Ferrero, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 26, 2024
Endometriosis-associated ovarian cancer: a different clinical entityUmberto Leone Roberti Maggiore, G Bogani, Biagio Paolini, et al.
Journal of Gynecologic Oncology|May 11, 2019
Efficacy and fertility outcomes of levonorgestrel-releasing intra-uterine system treatment for patients with atypical complex hyperplasia or endometrial cancer: a retrospective studyUmberto Leone Roberti Maggiore, Fabio Martinelli, Giulia Dondi, et al.
Expert Opinion on Investigational Drugs|July 19, 2021
Linzagolix: a new GnRH-antagonist under investigation for the treatment of endometriosis and uterine myomasSusan Dababou, Simone Garzon, Antonio Simone Laganà, et al.
Critical Reviews in Oncology/Hematology|May 16, 2018
Role of bevacizumab in uterine leiomyosarcomaGiorgio Bogani, Antonino Ditto, Fabio Martinelli, et al.
Hemasphere|May 26, 2023
Unmet Clinical Needs in the Management of Idiopathic Multicentric Castleman Disease: A Consensus-based Position Paper From an ad hoc Expert PanelPier Luigi Zinzani, Marco Paulli, Luca Arcaini, et al.
Expert Opinion on Investigational Drugs|November 1, 2016
Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancerAlice Bergamini, Simone Ferrero, Umberto Leone Roberti Maggiore, et al.
Annals of Medicine|September 3, 2021
Efficacy and safety of prolonged-release hyaluronic acid derivative vaginal application in the postpartum period: a prospective randomised clinical trialClaudio Gustavino, Paolo Sala, Nadia Cusini, et al.
Drugs|October 14, 2023
Current Medical Therapy for Adenomyosis: From Bench to BedsideAndrea Etrusco, Fabio Barra, Vito Chiantera, et al.
Annals of Hematology|April 23, 2016
Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective studyPatrizia Mondello, Normann Steiner, Wolfgang Willenbacher, et al.
Pageof 49